Prostaglandin Receptor

Receptor

Prostaglandin Receptor

Prostaglandin Receptor Isoform Specific Products:

Prostaglandin Receptor Isoform Comparison

Prostaglandin Receptor Related Products (605)
Antibodies (2)
Prostaglandin Receptor Isoform Comparison

By Effects:	Controls (50) Inhibitors (118) Ligand (1) Agonists (153) Degrader (1) Antagonists (132) Activators (24) Modulators (2) Inducer (1)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-19518

Latanoprostene bunod	Control	99.85%
Latanoprostene bunod (LBN), a nitric oxide (NO)-donating prostaglandin F2a analog, is a topical ophthalmic therapeutic for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension (OHT) .

HY-N3617

Coniferin		99.13%
Coniferin (Laricin) is a glucoside of coniferyl alcohol. Coniferin inhibits fungal melanization. Coniferin inhibits the release of certain hormones from cells, including Prostaglandin E2 and Thromboxane B2.

HY-10797

CJ-42794	Antagonist	98.96%
CJ-42794 (CJ-042794) is a potent, orally active, selective prostaglandin E receptor 4 (EP4) antagonist with an IC₅₀ value of 10 nM, which is 200-fold more selective than EP1, EP2 and EP3. CJ-42794 can be used in research of gastric ulcers.

HY-105218A

Ifetroban sodium	Antagonist	99.83%
Ifetroban (BMS-180291) sodium is an orally active antagonist of thromboxane A2 (TXA2) or prostaglandin H2 (PGH2) receptor. Ifetroban sodium shows antiplatelet activity, and inhibits tumor cell migration without affecting cell proliferation. Ifetroban sodium can be used for myocardial ischemia, hypertension, stroke, thrombosis, cardiomyopathy research.

HY-16504

Treprostinil sodium	Agonist	99.78%
Treprostinil (UT-15) sodium is a potent DP1 and EP2 agonist with EC₅₀ values of 0.6±0.1 and 6.2±1.2 nM, respectively.

HY-10794

MF498	Antagonist	99.26%
MF498 is a selective and orally active E prostanoid Receptor 4 (EP4) antagonist with a K_i value of 0.7 nM. MF498 can be used in the research of inflammation, such as rheumatoid and osteoarthritis.

HY-101987

BW 245C	Agonist	99.73%
BW 245C is a prostanoid DP-receptor (DP1) agonist, used to treat stroke.

HY-10413

MK-2894	Antagonist	99.31%
MK-2894 is a potent, selective, orally active and high affinity (K_i=0.56 nM) full antagonist against E prostanoid receptor 4 (EP4 receptor) (IC₅₀=2.5 nM). MK-2894 possesses potent anti-inflammatory activity in animal models of pain/inflammation and can be used for the research of arthritis.

HY-100009

Ufenamate	Inhibitor	99.89%
Ufenamate (Flufenamic acid butyl ester) is an anthranilic acid-based anti-inflammatory drug that can be used in the study of skin diseases such as acute and chronic eczema, contact dermatitis, diaper dermatitis, miliary rashes and atopic dermatitis. Ufenamate has a certain photoprotective effect, reduces the degree of skin erythema and swelling in the photoaging model, downregulates the expression level of COX-2 and can promote the healing of mouse skull defects by secreting BMP2.

HY-108562

SC-51322	Antagonist	98.90%
SC-51322 is a potent and selective antagonist of prostaglandin E2 (PGE₂) receptor (EP ₁), with a pA₂ of 8.1. SC-51322 has the pain-relieving effect.

HY-111271

L 888607	Agonist	99.87%
L 888607 is a potent, selective, stable and orally active CRTH2 agonist. L 888607 has high affinity for the human CRTH2 receptor with a K_i value of 4 nM. L 888607 can be used for the research of several physiological events and metabolite.

HY-100448A

Butaprost	Agonist	99.2%
Butaprost is a selective prostaglandin E receptor (EP2) agonist with an EC₅₀ of 33 nM and a K_i of 2.4 μM for murine EP2 receptor. Butaprost is less activity against murine EP1, EP3 and EP4 receptors. Butaprost attenuates fibrosis by hampering TGF-β/Smad2 signalling.

HY-B0428

Ozagrel	Inhibitor	99.74%
Ozagrel (OKY-046)is an anti-asthmatic agent and a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel is an antiplatelet agent, which selectively inhibits human platelet aggregation with an IC₅₀ of 53.12 μM.

HY-106961

ONO 1301	Agonist	99.06%
ONO 1301 (ONO-AP 500-02), a prostaglandin (PG) I2 mimetic, is an orally active, long-acting prostacyclin agonist with thromboxane-synthase inhibitory activity. ONO 1301 promotes production of hepatocyte growth factor (HGF) from various cell types and ameliorates ischemia-induced left ventricle dysfunction in the mouse, rat and pig.

HY-113331

Thromboxane B2	Control	99.00%
Thromboxane B2 is a prostaglandin derivative that is released during anaphylaxis. Thromboxane B2 induces arterial contraction and platelet aggregation.

HY-14973

Vidupiprant	Antagonist	98.33%
Vidupiprant (AMG 853) is a phenylacetic acid derivative. Vidupiprant is a potent and orally active CRTH2 (DP2) and prostanoid D receptor (DP or DP1) dual antagonist with IC₅₀s of 3 nM and 4 nM in buffer, and 8 nM and 35 nM in human plasma, respectively. Vidupiprant has the potential for asthma treatment.

HY-A0221

Ridogrel	Inhibitor	99.64%
Ridogrel (R 68070) is an orally active combined thromboxane A2 synthetase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor blocker. Ridogrel is potent antiplatelet agent. Anti-inflammatory activities.

HY-133123

EP4 receptor antagonist 1	Antagonist	99.66%
EP4 receptor antagonist 1 is a highly potent and selective competitive prostanoid EP4 receptor antagonist for cancer immunotherapy. EP4 receptor antagonist 1 inhibits human and mouse EP4 receptor with IC₅₀s of 6.1 nM and 16.2 nM, respectively. IC₅₀s >10 μM for human EP1, EP2,and EP3 receptors.

HY-112322

Carbacyclin	Agonist	98.00%
Carbacyclin is a PGI2 analogue, acts as a prostacyclin (PGI2) receptor agonist and vasodilator, and potently inhibits platelet aggregation.

HY-153129

EP2 receptor antagonist-2	Antagonist	98.69%
EP2 receptor antagonist-2 (CID891729) is an antagonist of EP2 receptor. EP2 receptor antagonist-2 inhibits the EP2 receptor activation induced by PGE2. EP2 receptor antagonist-2 also suppresses lactate dehydrogenase (LDH) release induced by N-methyl-D-aspartate (NMDA).

Prostaglandin E2		EP					99.76%
Prostaglandin E1		EP					99.76%
U-46619					TXA₂/TP		≥99.0%
Prostaglandin D2	DP						99.5%
Dinoprost			FP Receptor				99.63%
Tranilast	DP2, IC₅₀: 0.1 mM						99.58%
PF-04418948		EP2, IC₅₀: 16 nM					99.40%
ONO-AE3-208		EP4, Ki: 1.3 nM EP3, Ki: 30 nM	FP, Ki: 790 nM		TP Receptor, Ki: 2400 nM		98.65%
Latanoprost			FP Receptor				99.85%
Treprostinil			FP Receptor, Ki: 4680 nM	IP Receptor, EC₅₀: 1.9 nM IP Receptor, Ki: 32.1 nM	TP Receptor, EC₅₀: 919 nM		99.98%
Selexipag				hIP, Ki: 260 nM			99.86%
Iloprost				IP			99.76%
L-798106		EP3, IC₅₀: 0.3 nM EP4, IC₅₀: 916 nM EP1, IC₅₀: >5000 nM EP2, IC₅₀: >5000 nM					99.81%
DG-041		EP3, IC₅₀: 4.6-8.1 nM					≥99.0%
16,16-Dimethyl prostaglandin E2		EP2 EP4					≥99.0%
L-161982		EP4					99.04%
Laropiprant	DP, Ki: 0.57 nM				TP Receptor, Ki: 2.95 nM		99.93%
Grapiprant		dog EP4, IC₅₀: 35 nM dog EP4, Ki: 24 nM					99.57%
Asapiprant	DP1, Ki: 0.44 nM						99.53%
RO1138452				Rat I₂ Receptor, IC₅₀: 7 nM Rat I₂ Receptor, pKi: 8.33			≥98.0%
GW627368		EP					99.81%
Ginsenoside Ro					TXA₂		99.81%
Travoprost			FP				99.99%
Ramatroban	hDP2, IC₅₀: 113 nM hDP2, IC₅₀: 33.4 μM				hTP, IC₅₀: 14 nM		99.10%
Prostaglandin E2-d₄		EP					99.90%
Cefminox sodium				IP Receptor			99.83%
Omidenepag		hEP4, IC₅₀: 5480 nM hEP2, IC₅₀: 10 nM hEP2, EC₅₀: 1.1 nM					99.67%
L-902688		EP4, Ki: 0.38 nM EP4, EC₅₀: 0.6 nM					≥99.0%
Seratrodast					TXA₂/TP		98.86%
Nedocromil	PGD2						98.75%
NTP42					TXA₂		98.58%
MRE-269				IP Receptor			99.91%
Ebopiprant			Human FP Receptor, Ki: 1 nM Rat FP Receptor, Ki: 26 nM				98.65%
Pectolinarin		EP					99.89%
Fevipiprant	DP2, Kd: 1.14 nM						99.38%
AZD1981	DP						99.37%
Beraprost sodium				IP			99.88%
Omidenepag isopropyl		EP2					99.20%
TG4-155		EP2, Ki: 9.9 nM					99.91%
Prostaglandin J2	hDP, Ki: 0.9 nM hCRTH2, Ki: 6.6 nM	hEP1, Ki: 15.678 μM hEP2, Ki: 989 nM hEP3, Ki: 319 nM hEP4, Ki: 1065 nM	hFP, Ki: 553 nM	hIP, Ki: >25 μM	hTP, Ki: 6426 nM		98.10%
Timapiprant	DP						99.48%
Prostaglandin E2 (Standard)		EP
p-Hydroxycinnamic acid						TXB₂, IC₅₀: 371 μM	99.94%
CJ-42794		EP, EC₅₀: 10 nM					98.96%
Treprostinil sodium	DP1, EC₅₀: 0.6±0.1 nM DP1, Ki: 4.4 nM	EP2, EC₅₀: 6.2±1.2 nM EP2, Ki: 3.6 nM EP4, Ki: 826 nM EP3, Ki: 2505 nM EP1, Ki: 212 nM EP1, EC₅₀: 285 nM EP3, EC₅₀: 68.9 nM EP4, EC₅₀: 181 nM	FP Receptor, Ki: 4680 nM	IP Receptor, EC₅₀: 1.9 nM IP Receptor, Ki: 32.1 nM	TP Receptor, EC₅₀: 919 nM		99.78%
MF498		EP4, Ki: 0.7 nM					99.26%
BW 245C	DP						99.73%
SC-51322		EP2, pA2: 8.1					98.90%
L 888607	DP, Ki: 0.8 nM		FP Receptor, Ki: 10018 nM	IP Receptor, Ki: 14434 nM	TP Receptor, Ki: 283 nM		99.87%
Ozagrel					TXA₂		99.74%
Ridogrel		EP					99.64%
Carbacyclin				PGI₂ Receptor			98.00%
EP2 receptor antagonist-2		EP					98.69%
Latanoprost acid			FP				99.62%
Evatanepag		EP2					99.78%
MF-766		EP4, Ki: 0.23 nM					99.69%
Licarin A	DP						98.48%
(+)-Cloprostenol			PGF_2α				99.28%
CAY10471 Racemate	CRTH2, Ki: 0.6 nM						99.00%
Dinoprost tromethamine salt			FP Receptor				≥98.0%
EP3 antagonist 3		EP3, pKi: 8.3					99.52%
Setipiprant	hCRTH2, IC₅₀: 6 nM hDP1, IC₅₀: 1290 nM	EP2, IC₅₀: 2600 nM					98.23%
Sulprostone		EP3					≥99.0%
Epibetulinic acid		EP2, IC₅₀: 0.6 μM					≥98.0%
PDC31			FP Receptor, Ki: ~30 nM				99.76%
Ozagrel hydrochloride					TXA₂/TP		99.68%
SC 51089 free base		EP1, Ki: 1.3 μM EP3, Ki: 17.5 μM	FP, Ki: 61.1 μM		TP, Ki: 11.2 μM		98.64%
EP2 receptor antagonist-1		EP2					99.45%
EP4 receptor agonist 2		EP4, EC₅₀: 0.8 nM EP2, Ki: >100000 nM EP3, Ki: 38000 nM EP4, Ki: 3.1 nM					≥99.0%
Ralinepag	hDP1, EC₅₀: 850 nM			hIP, EC₅₀: 8.5 nM rIP, EC₅₀: 530 nM			99.79%
L-826266		EP3					≥98.0%
BI-671800	hCRTH2, IC₅₀: 4.5 nM mCRTH2, IC₅₀: 3.7 μM						99.36%
Taprenepag isopropyl		EP2					99.23%
BAY-6672 hydrochloride			FP				98.44%
BAY 73-1449				IP Receptor, IC₅₀: <0.1 nM			99.99%
Ozagrel sodium					TXA₂		99.98%
MK-7246	DP, Ki: 2.5 nM				TP, Ki: 3804 nM		99.63%
Treprostinil palmitil	DP						99.62%
SC-19220		EP					99.71%
Picotamide					TXA₂/TP		99.76%
BW A868C	DP2						99.00%
AAT-008		EP4, Ki: 0.97 nM EP4, IC₅₀: 6.1 nM					98.55%
Misoprostol acid		EP					≥99.0%
CAY10580		EP4, Ki: 35 nM EP2, Ki: 3000 nM EP3, Ki: 2000 nM EP1, Ki: >3000 nM
Darbufelone mesylate			PGF_2α				99.65%
Pexopiprant	DP2, Ki: <100 nM						99.40%
PROTAC(H-PGDS)-7	DP						99.42%
EP4-IN-1		EP4					99.94%
15-keto-Prostaglandin F2a			FP				99.2%
AMG-009	DP, IC₅₀: 12 nM CRTH2, IC₅₀: 3 nM						98.08%
PGN-9856		EP2, pEC₅₀: ≥ 8.5 EP2, pKi: ≥ 8.3					98.90%
Pizuglanstat	DP						99.70%
BAY-1316957		human EP4-R, IC₅₀: 15.3 nM					99.73%
Aganepag isopropyl		EP					98.61%
Nedocromil sodium	DP
KW-8232		EP					98.10%
Tafluprost acid		EP3, IC₅₀: 67 nM	Human FP Receptor, Ki: 0.4 nM Human FP Receptor, EC₅₀: 0.53 nM				99.80%
Daltroban					TXA₂		98.1%
Carboprost			FP				99.83%
Tiaprost			PGF_2α				≥98.0%
KP496					TXA₂ Receptor		99.79%
BGC-20-1531 free base		EP4, pKd: 7.6					98.05%
KW-8232 free base		EP
Aganepag		EP2, EC₅₀: 0.19 nM					99.71%
Treprostinil diethanolamine	DP1, Ki: 4.4 nM	EP2, Ki: 3.6 nM EP1, Ki: 212 nM EP4, Ki: 826 nM EP3, Ki: 2505 nM	FP, Ki: 4680 nM	IP, Ki: 32.1 nM			99.44%
Taprostene				IP
17-Phenyl-ω-trinor-PGE2		EP1 EP3					≥98.0%
L 888607 Racemate	DP1, Ki: 132 nM				TP, Ki: 17 nM		99.81%
Prostaglandin D2-d₉	DP						≥99.0%
Selexipag-d₇				IP			98.44%
Rivenprost		EP4, Ki: 0.7 nM					≥99.0%
CAY10471	CRTH2
SC 51089		EP1, Ki: 1.3 μM EP3, Ki: 17.5 μM	FP, Ki: 61.1 μM		TP, Ki: 11.2 μM
GSK-269984A		EP1, pIC₅₀: 7.9					99.74%
Carboprost tromethamine			FP				99.85%
ONO-8711		EP
Tranilast sodium	DP2, IC₅₀: 0.1 mM
Iloprost-d₄				IP
Sulotroban					TXA₂ Receptor
EP4 receptor antagonist 2		EP4, IC₅₀: 7.8 nM
Ifetroban					TXA₂/TP		99.65%
Cicaprost				IP
BAY-6672			FP
Laropiprant sodium	DP, Ki: 0.57 nM				TP, Ki: 2.95 nM
MK-8318	DP, Ki: 5.0 nM
GSK345931A		EP1
Prostaglandin E1-d₉		EP
(R)-Vorbipiprant		hEP4, Ki: 16.6 nM
Selexipag-d₆				IP
L-644698	hDP receptor, Ki: 0.9 nM	hEP2, Ki: 267 nM hEP3, Ki: 3730 nM hEP4, Ki: 9280 nM
MK-447				PGI₂
ASP7657 free base		hEP4, IC₅₀: 2.21 nM rat EP4, IC₅₀: 6.02 nM
Nocloprost		EP1 EP3
Travoprost (Standard)			FP
I-SAP					TXA₂ Receptor
2-(E-2-decenoylamino)ethyl 2-(cyclohexylethyl) sulfide				PGI₂
Treprostinil-¹³C₂,d	DP	EP
Prostaglandin E2-d₉		EP
Prostaglandin E1 (Standard)		EP
EP4 receptor agonist 1		hEP4, pEC₅₀: 6.3
Cloprostenol isopropyl ester			FP
Misoprostol acid-d₅		EP
TP-16		EP4, IC₅₀: 2.1 nM
AGN 210676	hDP receptor, EC₅₀: 7749 nM	EP2, EC₅₀: 5 nM hEP3, EC₅₀: 153 nM
CAY10535			FP Receptor		TP Receptor
Prostaglandin F2α dimethyl amine			FP
AMX12006		hEP4, IC₅₀: 4.3 nM
TG6-129		EP
Prostaglandin D2-d₄	DP
Saikogenin D		EP					99.99%
CAY10595	DP, Ki: 10 nM
Ramatroban-d₄					TXA₂/TP
Latanoprost (Standard)			FP Receptor
EP3 antagonist 6		EP3, IC₅₀: 1.9 nM
ICI 192605					TXA₂/TP
Etersalate					TXA₂
Terbogrel					TXA₂/TP
BM567					TXA₂ Receptor, IC₅₀: 1.1 nM TXA₂ synthase, IC₅₀: 12 nM
8-iso-15-keto Prostaglandin F2α			FP
11-Deoxy-16,16-dimethyl-PGE2		EP2 EP3
ER-819762		EP4, IC₅₀: 70 nM
Thromboxane A2					TP
EP2 receptor agonist 4		EP2, EC₅₀: 43 nM
L 657925					TXA₂
Prostaglandin A3		EP2, IC₅₀: 120 nM EP4, IC₅₀: 20 nM
CAY10509			FP, IC₅₀: 30 nM
CRTH2-IN-1	hDP2, IC₅₀: 6 nM hDP1, IC₅₀: 1 μM
LCB-2853					TXA₂ Receptor
AZ-1355				Prostaglandin I₂	TXA₂/TP		98.19%
RS-601					TXA₂ Receptor
CGS 15435					TXA₂, IC₅₀: 1 nM
BGC-20-1531		EP4
CI-949						TXB₂, IC₅₀: 0.1 μM
YM158 free base					TXA₂ Receptor, pA2: 8.81
Bunaprolast						TXB₂
KF 13218						TXB₂, IC₅₀: 5.3 nM

Name
Email *

	Sorry, but the email address you supplied was invalid.

Prostaglandin Receptor

Prostaglandin Receptor

Prostaglandin Receptor Isoform Specific Products:

Prostaglandin Receptor Isoform Specific Products:

Prostaglandin Receptor Related Products (605)

Antibodies (2)

Prostaglandin Receptor Isoform Comparison

Prostaglandin Receptor Related Products (605):